Xvivo Perfusion AB (publ)
XVIPF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$682.91M
Close$
$-13.50
162.2% downside
Current Fair Value
162.2% downsideOvervalued by 162.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $682.91 Million |
|---|---|
| Enterprise Value | $499.56 Million |
| Earnings per Share | $0.8 |
| Beta | 1.46 |
| Outstanding Shares | 31,499,470 |
Return
| Return on Equity | 5.86% |
|---|---|
| Return on Assets | 5.10% |
| Return on Invested Capital | 5.17% |
Valuation & Multiples
| P/E Ratio | 50.37 |
|---|---|
| PEG | 5.43 |
| Price to Sales | 0.72 |
| Price to Book Ratio | 0.31 |
| Enterprise Value to Revenue | 0.52 |
| Enterprise Value to EBIT | 4.14 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 22, 2026
EPS Estimate
$0.06
Consensus analyst estimateRevenue Estimate
$23.47 M
Consensus analyst estimateNext Earnings Call
Expected Date
January 28, 2027
EPS Estimate
$0.09
Consensus analyst estimateRevenue Estimate
$26.24 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Xvivo Perfusion AB (publ)
210 employees
CEO: Christoffer Rosenblad
Xvivo Perfusion AB (publ) is a specialized medtech company creating advanced technologies for the preservation and perfusion of organs, tissues, and cells, vital for successful transplantation. Founded in 1998 and headquartered in Gothen...